Dr. Pere Domingo

Autonomous Unversity of Barcelona, Spain

Email: [email protected]

Qualifications

1992  Ph.D., Universitat Autònoma de Barcelona, Spain

1979  M.D., Universidad de Barcelona, Spain

1973  B.S., Universidad de Barcelona, Spain

Publications (Selected)

1. Català-Moll, F., Blázquez-Bondia, C., Farré-Badia, J., et al. (2026). Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial ( vol 17 , 2022 , 2026). Nature Communications, 17(1), Artículo 3817.
2. Català-Moll, F., Blázquez-Bondia, C., Farré-Badia, J., et al. (2026). Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. Nature Communications, 17(1), Artículo 2022.
3. Domingo, P., Waters, L., Masiá, M., et al. (2023). Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir. Journal of Antimicrobial Chemotherapy, 78(9), 2361–2365.
4. Berenguer, J., Jarrin, I., Bellón, J., et al. (2022). Genetic contribution to weight gain after initiation of antiretroviral therapy in treatment-naive patients with HIV. Journal of the International AIDS Society, 25(Supl. 6), 139–140.
5. Martin-Iguacel, R., Vazquez-Friol, M., Burgos, J., et al. (2022). Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study. Journal of the International AIDS Society, 25(Supl. 6), 132–134.
6. Martin-Iguacel, R., Reyes-Urueña, J., Casabona, J., et al. (2022). Determinants of long-term survival in late HIV diagnosed individuals: the PISCIS Cohort study. Journal of the International AIDS Society, 25(Supl. 3), 25–26.
7. Mocroft, A., Miro, JM., Wandeler, G., et al. (2021). The association between hepatitis B infection and malignancies in persons living with HIV: results from the EuroSIDA study. HIV Medicine, 22(Supl. 3), 168–169.
8. Nomah, DK., Díaz, Y., Martinez, E., et al. (2021). A population-based assessment of SARS-CoV-2 testing, test positivity, and clinical severity between the general population and people living with HIV in Catalonia, Spain (March-December 2020). HIV Medicine, 22(Supl. 3), 199–199.
9. Martin-Ezquerra, G., Monreal, P., Mercuriali, L., et al. (2021). Evolution of notified sexually transmitted infections in Barcelona during the first wave of the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology, 35(10), E642–E645.
10. Nomah, DK., Reyes-Urueña, J., Diaz, Y., et al. (2021). CD4+T-cell count below 200 cells/mm3 is associated with worse COVID-19 outcomes among people living with HIV regardless of virological suppression. Journal of the International AIDS Society, 24(Supl. 4), 12–13.
11. Prat, DL., Castellví, I., Castillo, D., et al. (2021). PROGNOSTIC VALUE OF SERUM KREBS VON DEN LUNGEN-6 GLYCOPROTEIN CIRCULATING LEVELS IN COVID-19 PNEUMONIA: A PROSPECTIVE COHORT STUDY. Annals of the Rheumatic Diseases, 80(Supl. 1), 1365–1365.
12. Domingo, P., Quesada-López, T., Villarroya, J., et al. (2020). Differential effects of raltegravir, dolutegravir and bictegravir on human adipocytes. Journal of the International AIDS Society, 23(Supl. 7), 74–74.
13. Rojas, J., Blanco, JL., Negredo, E., et al. (2020). Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR). Journal of the International AIDS Society, 23(Supl. 4), 110–110.
14. Amele, S., Peters, L., Sluzhynska, M., et al. (2019). Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. HIV Medicine, 20(4), 264–273.
15. Linares, MS., Sánchez-Quesada, JL., Assoumou, L., et al. (2018). Favourable phenotype of LDL particles in subjects with high cardiovascular risk switching from a ritonavir-boosted protease inhibitor to dolutegravir. Results of the NEAT 022 study. Antiviral Therapy, 23(Supl. 1), A31–A31.
16. Villarroya, J., Artigas, N., Sánchez-de-Diego, C., et al. (2018). HIV-1 transgene expression in mice: a model for non-drug-mediated alterations in metabolism, adiposity and bone homeostasis in patients. Antiviral Therapy, 23(Supl. 1), A6–A6.
17. Molina, J., Gil, L., Luño, V., et al. (2017). Alternative treatment for vaginitis in the bitch. Reproduction in Domestic Animals, 52(Supl. 4), 88–88.
18. Santos, JR., Llibre, JM., Domingo, P., et al. (2011). Mutations in the protease gene and factors associated with virological failure to lopinavir/ritonavir-containing regimens in clinical samples. Antiviral Therapy, 16(Supl. 1), A78–A78

Profiles Details
https://www.researchgate.net/profile/Pere-Domingo-2
https://scholar.google.com/citations?user=Oi4ao2UAAAAJ&hl=es

WOS ResearcherID: PPE-1432-2026